OCUP

Stats

Summary

ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. ocuphire’s lead drug candidate, nyxol eye drops, is aimed to treat patients with night vision disturbances (nvd), glaucoma and presbyopia (impaired near-term vision). ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.

Market Cap: 54.8 Million

Primary Exchange: NASDAQ

Website: https://www.rexahn.com/

Shares Outstanding: 22.6 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.397863966857176

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 799 trading days

From: 2021-02-03 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor